Financial Performance

  • Revenue from operations for Apr-Jun FY27: ₹99.60 crore (INR 9,960.22 lakhs)
  • Achieved nearly 50% of previous financial year's full-year revenue in first quarter
  • Improved margins compared to previous periods

Subsidiary Update - Vinstar Biotech Private Limited

  • Received trial orders from multiple customers for value-added ingredients developed in-house
  • Order sizes described as modest but significant for validating R&D capabilities
  • Marks group's first steps as developer of proprietary formulations rather than just ingredient supplier

Manufacturing Facility Progress - Easy Raw Materials Private Limited

  • Manufacturing facility development progressing on schedule within planned timeline
  • Civil work progressing as per plan
  • Electricity sanction letter received for power infrastructure
  • Packaging machinery finalized, with delivery expected within 30-35 days of PO release
  • Company committed to communicate any delays in project schedule to stakeholders

Business Development

  • Added 20 new customers during Apr-Jun FY27
  • 15 R&D projects in pipeline
  • Participated in three key industry exhibitions across India and Europe in first half of 2026
  • Celebrated Nutrition Day and Yoga Day internally

Strategic Direction

Company is transitioning from product supplier to solutions partner by:

  • Investing in Research & Development
  • Providing complete customized solutions including ingredient selection, application support, formulation guidance
  • Building scalable processes aligned with manufacturing integration
  • Improving sourcing efficiency and turnaround timelines

Expansion Plans

Strategic expansion into functional and value-added ingredient categories including:

  • Proteins
  • Functional fibers
  • Salt reduction solutions

Market Outlook

  • Global nutraceutical industry showing strong upward trajectory
  • Asia-Pacific dominating global demand and supply dynamics
  • Key trends: preventive healthcare, functional ingredients, science-backed formulations, supply chain diversification
  • Industry moving from volume-driven to value-driven, science-backed ecosystems

Forward-looking Statements

  • Commissioning of EZRM manufacturing facility with sequenced machine deliveries
  • Scaling R&D investment and customized solutions offering
  • Strengthening global sourcing footprint and long-term supplier partnerships
  • Sustaining strong revenue growth through consistent CAGR-driven execution

Investor Relations Contacts

  • Rasika Sawant: rasika@x-b4.com, +91-9594457518
  • Aagam Shah: aagam@x-b4.com, +91-8850166932

Disclaimer

This update is for information purposes only and does not constitute an offer or recommendation to purchase securities. Contains forward-looking statements subject to risks and uncertainties. Figures are unaudited unless otherwise stated.